Fig. 2
From: Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan
Successful production of skeletal muscle-specific Pomt1-deficient mice. A Schematic depicting O-mannosylated dystroglycan in the sarcolemma of control and Pomt1-deficient skeletal muscle (Pomt1skm). B Immunofluorescence for matriglycan (recombinant rabbit IIH6 antibody) and the C-terminus of β-DG (rabbit polyclonal AP83 antibody) in transverse cross-sections of the gastrocnemius muscle from control or Pomt1skm mice. Images captured at 40X magnification. Scale bar = 100 µm. C Western blot analysis of pooled skeletal muscle samples from 13-week-old female control and Pomt1skm mice. The monoclonal IIH6 antibody was used to detect matriglycan and the AF6868 rabbit polyclonal antibody was used to detect core DG. D Pictures of two Pomt1skm mice alongside littermate controls. All four mice were 4 weeks of age. E Body weights of Pomt1.skm and age- / gender-matched controls at 4-, 8-, and 12 weeks of age. Data are expressed as mean ± standard deviation. P-values determined by unpaired t-tests with Holm-Sidak post-hoc analysis. Males: ** = 0.0011; *** = 0.0008; **** < 0.00001. Females: ns, not significant; * = 0.0161; *** = 0.0007